AbbVie, Inc. Hits New 52-Week High of $225.16, Showcasing Strong Performance

AbbVie, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 225.16 on September 22, 2025. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 30.58%, significantly outpacing the S&P 500's growth of 16.64% during the same period.
With a market capitalization of approximately USD 377.73 billion, AbbVie stands as a large-cap entity within its industry. The company's price-to-earnings (P/E) ratio is currently at 23.00, reflecting its valuation in the market. Additionally, AbbVie boasts an impressive dividend yield of 150.59%, which may appeal to income-focused investors.

Despite the positive price movement, AbbVie has reported a negative return on equity of -8,165.01%, indicating challenges in generating profit from shareholders' equity. The stock's 52-week low was recorded at USD 163.81, highlighting the significant upward trajectory it has experienced in recent months. This milestone reinforces AbbVie's position in the competitive pharmaceutical landscape.